BeOne Medicines Ltd.: management transactions · United States · SEC (Form 4)

About BeOne Medicines Ltd.

BeOne Medicines Ltd. is a global biopharmaceutical company listed on the NASDAQ (United States) under the ticker ONC, with additional listings in Hong Kong and Shanghai. The company, formerly known as BeiGene, completed a name change and redomiciliation on May 27, 2025, moving its place of incorporation from the Cayman Islands to Switzerland while keeping its Nasdaq Global Select Market listing intact. For international investors, this means BeOne is a U.S.-listed oncology company with a Swiss legal domicile and a globally distributed operating footprint. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1651308/000110465925053039/tm2515777d11_posasr.htm)) Founded in 2010 by John V. Oyler and Xiaodong Wang, BeOne was built around a clear mission: to develop innovative cancer therapies and make them more accessible across global markets. The company’s operational footprint spans major hubs including San Carlos, California; Cambridge, Massachusetts; and Basel, Switzerland, alongside manufacturing and R&D capabilities in the United States, China, Europe, and Latin America. BeOne also highlights a broad global research network, with clinical development and commercial activities across multiple continents. ([beonemedicines.com](https://beonemedicines.com/about/history/?utm_source=openai)) BeOne is primarily an oncology-focused business. Its commercial foundation rests on two key medicines: BRUKINSA (zanubrutinib), a BTK inhibitor used in several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy used in solid tumors and hematologic indications. Beyond these marketed products, the company is advancing a broad pipeline that spans blood cancers, lung cancer, breast/gynecological cancers, gastrointestinal cancers, and certain rare cancers. BeOne states that it has more than 30 investigational medicines in development, underscoring a pipeline-driven growth model rather than a narrow single-asset profile. ([beonemedicines.com](https://beonemedicines.com/science/medicines/?utm_source=openai)) From a competitive perspective, BeOne operates in a highly crowded oncology landscape against major global pharma groups and specialist biotech peers. Its differentiation lies in an integrated development model, a wide geographic commercialization strategy, and a stated focus on improving patient access. The company reports regulatory approvals for its internally developed medicines in more than 75 countries, which gives it meaningful international reach and supports the view that it is building a global oncology platform rather than a purely regional business. ([beonemedicines.com](https://beonemedicines.com/about/our-company/faqs/?utm_source=openai)) Recent developments have been constructive. In February 2026, BeOne reported full-year 2025 revenue of $5.3 billion and highlighted strong global momentum for BRUKINSA. In May 2026, the company announced U.S. FDA approval of BEQALZI (sonrotoclax), and it also received FDA Priority Review for TEVIMBRA in a HER2-positive first-line indication. These updates reinforce the company’s clinical execution and regulatory momentum, both of which are central to the investment case in oncology biotech. ([ir.beonemedicines.com](https://ir.beonemedicines.com/news/beone-medicines-announces-fourth-quarter-and-full-year-2025-financial-results-highlighting-global-success-of/6559b41c-7beb-45ca-bc76-5e1c9cdb26cc?utm_source=openai))